Episode 872: Ibogaine – Inside a Treatment Facility

Newt's World

Gingrich 360

News, Politics

4.7 • 6.3K Ratings

🗓️ 19 July 2025

⏱️ 36 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Newt talks with Jonathan Dickinson, CEO and José Inzunza, Chief Medical Officer, Co-Founders of Ambio Life Sciences, a global leader in integrative Ibogaine treatment. They discuss the potential of Ibogaine as a therapy for post-traumatic stress disorder, opioid addiction, and depression. Ibogaine is classified as a Schedule I controlled substance by the U.S. Drug Enforcement Agency and is primarily administered in treatment facilities outside the U.S., such as in Mexico and Canada. They talk about their experiences administering Ibogaine and insights into its therapeutic effects, particularly the ability to mitigate opioid withdrawal symptoms and improve neurological health. They also highlight the importance of patient preparation and the need for ongoing support post-treatment to prevent relapse. Ambio Life Sciences collaborated with Stanford University and their pioneering clinical program for neurodegenerative diseases to study conditions like Parkinson's and multiple sclerosis. Their discussion underscores Ibogaine's potential to revolutionize addiction treatment and neurological health.

See omnystudio.com/listener for privacy information.

Transcript

Click on a timestamp to play from that location

0:00.0	This is an I-Heart podcast.
0:08.5	On this episode of Neutral World, I've been doing a series of podcasts in Ibogain as a
0:13.6	potentially effective therapy for treating post-traumatic stress disorder, opioid addiction,
0:19.2	and depression.
0:22.8	Ibogaine is a level one substance as classified by the Drug Enforcement Agency in United States, so many of the treatment facilities
0:28.5	are located in other countries, including Mexico and Canada. After my conversations with both
0:35.3	W. Brian Hubbard from Americans for Ibogaine and Dr. Nolan Williams,
0:40.5	who conducted a Stanford study on Ibogaine, I was contacted by Ambio Life Sciences, a company
0:47.3	based in Mexico that administers ibogane treatments. They have a great deal of experience in treating
0:53.0	patients who come to their facility for ibogane
0:56.0	therapy.
0:56.9	So I wanted to have them on to talk about the process of what patients experience.
1:02.7	I'm really pleased to welcome my guest, Jonathan Dickinson, CEO, and Jose Inzunza, chief medical
1:09.5	officer.
1:10.4	They are both co-founders of Ambio Life Sciences,
1:14.0	a global leader in integrative Ibogaine Treatment.
1:32.3	Jonathan and Jose, welcome and thank you for joining me on Nutsworld.
1:35.1	Thank you very much, sir. It's a honor to be here.
1:36.5	Thank you so much for the time.
1:43.5	Jonathan, you've been working with iBoga and Ibogain since 2009, both clinically and ceremonially.
1:47.0	What originally drew you to this work and how has your understanding of its potential evolved over time? Yeah, so I began working with Ibegain in
1:54.4	late 2009 and had to come down here to Mexico to begin doing that work.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Gingrich 360, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Gingrich 360 and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.